The Drugs Controller General of India (DGCI) has given emergency approval authorisation on Friday for the use of ‘Virafin’, Pegylated Interferon alpha – 2b (PegIFN) for treatment of moderate Covid-19 infections in adults. A single dose of Virafin will accelerate the treatment and make it more convenient.
When administered in the early phase during Covid-19, it will pace up the recovery process, and avoid much of complications.
Amid the release, Cadila emphasized that “drug has also shown efficacy against other viral infections.” While addressing the development, Dr Sharvil Patel, Managing Director of Cadila Healthcare Limited said, “The fact that we are able to offer a therapy which significantly reduces the viral load when given early on can help in better disease management. It comes at a much-needed time for patients and we will continue to provide them access to critical therapies in this battle against COVID-19.”
During the phase-3 clinical trials, the therapy had depicted progressive clinical improvement for the patients suffering from Covid-19. The patients in a higher majority showed a very positive response and exhibited a negative response for RT-PCR by day 7.
The drug assures rapid viral clearance and has various add-on benefits when comparing with other anti-viral agents. The approval has been given during the ongoing second wave of Covid-19 in the country.
- Bengaluru metro to function on weekdays, closed on weekends from July 1
- India provides reciprocal exemption of EU Digital COVID Certificate to include Covishield, Covaxin
- PM Modi will address the Digital India beneficiaries at 11 am tomorrow
- Pvt hospitals will obtain Covid vaccine doses via CoWIN starting from July 1
- DGCA further extends the ban on international flights till July 31 due to Covid-19